
Commentary|Podcasts|July 1, 2025
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.
Advertisement
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure, as well as findings from the FAIR-HF2 clinical trial.
Show notes:
- Anker SD, Friede T, Butler J, et al.
Intravenous ferric carboxymaltose in heart failure with iron deficiency . JAMA. 2025;333(22):1965-1976. doi:10.1001/jama.2025.3833 - Kido K, Fang W, Broscious R, et al.
Evaluation of a pharmacist-provider collaborative clinic for treatment of iron deficiency in patients with heart failure . Am J Health Syst Pharm. 2023;80(19):1326-1335. doi:10.1093/ajhp/zxad149 - Kido K, Beavers CJ, Dulnuan K, et al.
Management of iron deficiency in heart failure: practical considerations and implementation of evidence-based iron supplementation . JACC Heart Fail. 2024;12(12):1961-1978. doi:10.1016/j.jchf.2024.05.014 Scientific Statement on Diagnosis and Treatment of Iron Deficiency in Heart Failure Released by Heart Failure Society of America . News release. HFSA. May 2, 2023. Accessed June 27, 2025.- Antrim A.
Enhancing Patient Care in Heart Failure-Related Anemia Through Improved Communication, Monitoring, and Education . Pharmacy Times. March 17, 2025. Accessed June 27, 2025.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Imlunestrant Tablets for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
2
IMWG Consensus Risk Criteria Predicts Survival in Daratumumab Quadruplet Therapy
3
Linvoseltamab Monotherapy Elicits Promising ORR, MRD-Negativity in NDMM
4
How Pharmacists Support CDK4/6 Inhibitor Management and Patient Care
5